Project Updates and Milestones news (page 36)

28 March 2026

Takeda’s Zasocitinib: Once‑daily pill achieves rapid, durable clearance in plaque psoriasis

Phase 3: ~70% reached sPGA 0/1 at week 16; PASI90 up to 61%, PASI100 up to 33%. Responses rose through week 24 and >90% of responders maintained effect to week 60. Safety consistent with prior studies
28 March 2026

Johnson & Johnson STEMI-DTU RCT: LV unloading with delayed reperfusion does not increase infarct size

Neutral trial. 30‑min Impella improved pre‑PCI TIMI flow. Age 61+ trended smaller infarcts. More bleeding/vascular events but no higher 12‑month mortality. Elevated lactate predicted larger infarcts.
28 March 2026

Johnson & Johnson: ICOTYDE (icotrokinra) 52‑week data show sustained skin clearance and favorable safety

ICONIC Phase 3: PASI100 rose to 49%/48% (ADVANCE 1/2) by Week52; placebo switchers matched. Adolescents: 57% PASI100, 86% PASI90 at 52w. No new safety signals; fewer AEs vs deucravacitinib.
28 March 2026

Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity

Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).
27 March 2026

EMA recommends Amgen’s Imdylltra for relapsed extensive‑stage SCLC

EMA backs EU approval for a bispecific T‑cell engager for relapsed extensive‑stage SCLC post‑platinum; phase 3: OS 13.6 vs 8.3 months. Main risks: CRS, ICANS
27 March 2026

Sasol — Middle East developments and business impact

Middle East conflict disrupted gas supply - ORYX GTL shut; ~60 staff safe. Fuel and chemicals impacted; Secunda/Natref secure inventories and alternative crude; contingencies active.

The right choices in the European chemical industry

Save time with chemXplore Alpha

Learn more

← Previous Next →